Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform. This role ensures that all product testing, stability programs, and environmental monitoring workflows-whether executed in-house or by third-party vendors-strictly adhere to cGMP, data integrity regulations, and global health authority expectations.